This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
AJANI, JAFFER A
| Item Type | Name |
|
Academic Article
|
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
|
|
Academic Article
|
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer.
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Vascular Endothelial Growth Factor D
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Academic Article
|
The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer.
|
|
Academic Article
|
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer.
|
|
Academic Article
|
New pharmacological developments in the treatment of hepatocellular cancer.
|
|
Academic Article
|
Modern oncological approaches to gastric adenocarcinoma.
|
|
Academic Article
|
Ramucirumab: a novel antiangiogenic agent.
|
|
Academic Article
|
Anti-angiogenic agent ramucirumab: meaningful or marginal?
|
|
Academic Article
|
Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer.
|
|
Academic Article
|
Molecular biomarkers in gastric cancer.
|
|
Academic Article
|
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
|
|
Academic Article
|
Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets.
|
|
Academic Article
|
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
|
|
Academic Article
|
Targeting Angiogenesis in Colorectal Carcinoma.
|
|
Academic Article
|
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
|
|
Academic Article
|
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
|
- Vascular Endothelial Growth Factor A